AtheroGenics, Inc. (Nasdaq: AGIX), a pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of chronic inflammatory diseases, has named G. John Mohr as vice president of business development.

In this role, AtheroGeneics says Mohr, a pharmaceutical industry veteran, will manage strategic alliance relationships and partnership opportunities in support of the company’s aggressive business plan.

“John brings to our team a rare combination of demonstrated leadership and business development expertise for managing our strategic alliance partnerships and carving out licensing opportunities,” Russell M. Medford, president and chief executive officer of AtheroGenics, said in a statement.

Mohr joins AtheroGenics from Fournier Pharma Inc., a subsidiary of Groupe Fournier, where he was president of U.S. operations. Previously, Mohr was director of pharmaceutical business development at Perrigo Company, in charge of new business development activities for the nation’s largest manufacturer of OTC pharmaceuticals and personal care products. Mohr also brings more than 10 years of experience as marketing director for Merck & Co., Inc in the human health division.